You are here

Article info

Article menu

Download PDFPDF

XML
Commentary
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer

Authors

  • Peter Paul Yu Hartford HealthCare Cancer Institute and Memorial Sloan Kettering Cancer CenterHartford Hospital 80 Seymour Street 06102-5037 Hartford CT USA PubMed articlesGoogle scholar articles
  • Omar Eton Hartford HealthCare Cancer Institute 80 Seymour Street 06102-5037 Hartford CT USA PubMed articlesGoogle scholar articles
  • Louis P. Garrison The Comparative Health Outcomes, Policy, and Economics (CHOICE) InstituteUniversity of Washington Box 357630 Health Sciences Building, H375, 1959 NE Pacific Street 98195-7630 Seattle WA USA PubMed articlesGoogle scholar articles
  1. ↵a Peter.Yu{at}hhchealth.org
  2. ↵b Omar.Eton{at}hhchealth.org
  3. ↵c lgarrisn{at}uw.edu
View Full Text

Citation

Yu PP, Eton O, Garrison LP
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
Journal for ImmunoTherapy of Cancer 2019;7:235. doi: 10.1186/s40425-019-0707-9

Publication history

  • Received January 20, 2019
  • Accepted August 14, 2019
  • First published September 3, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.